<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03197077</url>
  </required_header>
  <id_info>
    <org_study_id>2017.corifollitropinalfa_IVM</org_study_id>
    <nct_id>NCT03197077</nct_id>
  </id_info>
  <brief_title>Optimisation of Follicular Recruitment in IVM Cycles</brief_title>
  <acronym>Elonva_IVM</acronym>
  <official_title>A Comparison Between Corifollitropin Alfa and Recombinant FSH for Follicular Recruitment in Women With Polycystic Ovaries Who Undergo IVM Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitair Ziekenhuis Brussel</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Universitair Ziekenhuis Brussel</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will focus on important aspects related to follicle recruitment using exogenous
      gonadotropins in patients with polycystic ovaries:

        1. Early follicle recruitment in patients with polycystic ovaries using corifollitropin
           alfa: does administration of this drug result in earlier and higher FSH (follicle
           stimulating hormone) concentrations above the threshold for follicle recruitment in an
           IVM (in vitro maturation) cycle preceded by oral contraceptive suppression, in
           comparison to normal daily administration of rFSH (recombinant follicle stimulating
           hormone, Puregon)?;

        2. The maturation rate of the obtained oocyte-cumulus complexes in standard IVM media
           registered for clinical use: does stimulation with corifollitropin alfa versus
           recombinant FSH have an impact on the maturation rate and developmental capacity of the
           oocytes ?
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2018</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of COC</measure>
    <time_frame>5 days after the first gonadotropin injection (on the day of oocyte retrieval)</time_frame>
    <description>Number of oocyte cumulus complexes obtained on the day of oocyte retrieval.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical pregnancy rate</measure>
    <time_frame>At about 6 - 7 weeks gestation</time_frame>
    <description>Clinical pregnancy rate after the first embryo transfer following the IVM cycle</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">145</enrollment>
  <condition>Infertility, Female</condition>
  <condition>Polycystic Ovary Syndrome</condition>
  <arm_group>
    <arm_group_label>Elonva</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single injection of 100 microgram corifollitropin alfa. Oocyte retrieval on day five after corifollitropin alfa injection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Puregon</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Three daily injections of 150 IU follitropin beta. Oocyte retrieval on day five after the first follitropin beta injection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>blood sampling</intervention_name>
    <description>comparison between corifollitropin alfa and follitropin beta in IVM cycles</description>
    <arm_group_label>Elonva</arm_group_label>
    <arm_group_label>Puregon</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>transvaginal ultrasound scanning</intervention_name>
    <description>comparison between corifollitropin alfa and follitropin beta in IVM cycles</description>
    <arm_group_label>Elonva</arm_group_label>
    <arm_group_label>Puregon</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>oocyte retrieval for IVM</intervention_name>
    <description>comparison between corifollitropin alfa and follitropin beta in IVM cycles</description>
    <arm_group_label>Elonva</arm_group_label>
    <arm_group_label>Puregon</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Corifollitropin Alfa</intervention_name>
    <description>Single injection of 100 micrograms of corifollitropin alfa</description>
    <arm_group_label>Elonva</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Follitropin beta</intervention_name>
    <description>Daily injection (three days) of follitropin beta</description>
    <arm_group_label>Puregon</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oral contraceptive pill pretreatment (Marvelon)</intervention_name>
    <description>Daily administration of the oral contraceptive pill (Marvelon) for 21 days. Administration of the combined oral contraceptive pill will start after a blood test that demonstrates basal E2 levels and a negative serum hCG level.</description>
    <arm_group_label>Elonva</arm_group_label>
    <arm_group_label>Puregon</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subfertile patients between 18-36 years old eligible for ART treatment

          2. BMI 18-30

          3. Polycystic ovaries (PCO) according to the Rotterdam criteria (at least 12 antral
             follicles per ovary as observed on a baseline ultrasound scan), with or without
             hyperandrogenism, with or without oligoamenorrhoea. In other words, patients are
             eligible if they have PCO morphology. A diagnosis of PCOS (polycystic ovary syndrome)
             based on Rotterdam criteria is not compulsory.

        Exclusion Criteria:

          1. Antral follicle count (AFC) &lt;24

          2. Anti-m√ºllerian hormone (AMH) &lt;3,25 in non-OCP (oral contraceptive pill) users and
             &lt;4,00 in current OCP users (using Elecsys platform (Roche Diagnostics))

          3. Couples requesting PGD (preimplantation genetic diagnosis)

          4. Non-obstructive azoospermia in the male partner
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>36 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Elsie Nulens</last_name>
    <phone>+3224776648</phone>
    <email>elsie.nulens@uzbrussel.be</email>
  </overall_contact>
  <location>
    <facility>
      <name>UZ Brussel</name>
      <address>
        <city>Brussels</city>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elsie Nulens</last_name>
      <phone>+3224776648</phone>
      <email>elsie.nulens@uzbrussel.be</email>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 16, 2017</study_first_submitted>
  <study_first_submitted_qc>June 22, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 23, 2017</study_first_posted>
  <last_update_submitted>May 8, 2018</last_update_submitted>
  <last_update_submitted_qc>May 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universitair Ziekenhuis Brussel</investigator_affiliation>
    <investigator_full_name>Michel De Vos</investigator_full_name>
    <investigator_title>Medical director</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
    <mesh_term>Polycystic Ovary Syndrome</mesh_term>
    <mesh_term>Infertility, Female</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Contraceptive Agents</mesh_term>
    <mesh_term>Desogestrel</mesh_term>
    <mesh_term>Contraceptives, Oral</mesh_term>
    <mesh_term>Follicle Stimulating Hormone</mesh_term>
    <mesh_term>Contraceptives, Oral, Combined</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

